These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19718394)

  • 61. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
    Yamazaki S; Ichimura S; Iwamoto J; Takeda T; Toyama Y
    J Bone Miner Metab; 2004; 22(5):500-8. PubMed ID: 15316873
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
    Ringe JD; Schacht E
    Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis.
    Kitazaki S; Mitsuyama K; Masuda J; Harada K; Yamasaki H; Kuwaki K; Takedatsu H; Sugiyama G; Tsuruta O; Sata M
    Aliment Pharmacol Ther; 2009 Feb; 29(4):424-30. PubMed ID: 19035979
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bisphosphonate use in children with cerebral palsy.
    Hurley T; Zareen Z; Stewart P; McDonnell C; McDonald D; Molloy E
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD012756. PubMed ID: 34224134
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and safety of alfacalcidol in Chinese postmenopausal women aged over 65 with osteoporosis or osteopenia: An open label, non-comparative, post marketing observational study.
    Li N; Jiang Y; He S; Zhao Z; Sun J; Li M; Wang O; Xing X; Xia W
    Medicine (Baltimore); 2018 Nov; 97(47):e13159. PubMed ID: 30461612
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
    Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
    J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study.
    Schacht E; Ringe JD
    Arzneimittelforschung; 2011; 61(1):40-54. PubMed ID: 21355445
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
    Iwamoto J; Seki A; Takeda T; Sato Y; Yamada H; Yeh JK
    J Nutr Sci Vitaminol (Tokyo); 2006 Feb; 52(1):1-8. PubMed ID: 16637224
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial.
    Jiang Y; Zhang ZL; Zhang ZL; Zhu HM; Wu YY; Cheng Q; Wu FL; Xing XP; Liu JL; Yu W; Meng XW
    Clin Interv Aging; 2014; 9():121-7. PubMed ID: 24426779
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Alendronate therapy in men with primary hyperparathyroidism.
    Khan AA; Bilezikian JP; Kung A; Dubois SJ; Standish TI; Syed ZA
    Endocr Pract; 2009; 15(7):705-13. PubMed ID: 19625240
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A prospective analytical study of the effects and adverse events of alendronate (Aldren70) treatment in Thai postmenopausal women.
    Tienboon P; Jaruwangsanti N
    J Med Assoc Thai; 2014 Jun; 97(6):621-8. PubMed ID: 25137879
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
    Takakuwa M; Iwamoto J; Konishi M; Zhou Q; Itabashi K
    J Bone Miner Metab; 2011 Jan; 29(1):88-95. PubMed ID: 20533068
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.